The RATPAC (Randomised Assessment of Treatment using Panel Assay of Cardiac markers) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department
Open accessThe DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of using a point-of-care cardiac marker panel in patients presenting to the emergency department (ED) with suspected but not proven acute myocardial infarction (AMI). DESIGN: Multicentre pragmatic open randomised controlled trial and economic evaluation. SETTING: Six acute hospital EDs in the UK. PARTICIPANTS: Adults presenting to hospital with chest pain due to suspected but not proven myocardial infarction, and no other potentially serious alternative pathology or comorbidity. INTERVENTIONS: Participants were allocated using an online randomisation system to receive either (1) diagnostic assessment using the point-of-care biochemical marker panel or (2) conventional diagnostic assessment without the panel. All tests and treatments other than the panel were provided at the discretion of the clinician. MAIN OUTCOME MEASURES: The primary outcome was the proportion of patients successfully discharged home after ED assessment, defined as patients who had (1) either left the hospital or were awaiting transport home with a discharge decision having been made at 4 hours after initial presentation and (2) suffered no major adverse event (as defined below) during the following 3 months. Secondary outcomes included length of initial hospital stay and total inpatient days over 3 months, and major adverse events (death, non-fatal AMI, life-threatening arrhythmia, emergency revascularisation or hospitalisation for myocardial ischaemia). Economic analysis estimated mean costs and quality-adjusted life-years (QALYs), and then estimated the probability of cost-effectiveness assuming willingness to pay of £20,000 per QALY gained. RESULTS: We randomised 1132 participants to point of care and 1131 to standard care, and analysed 1125 and 1118, respectively [mean age 54.5 years, 1307/2243 (58%) male and 269/2243 (12%) with known coronary heart disease (CHD)]. In the point-of-care group 358/1125 (32%) were successfully discharged compared with 146/1118 (13%) in the standard-care group [odds ratio (OR) adjusted for age, gender and history of CHD 3.81; 95% confidence interval (CI) 3.01 to 4.82, p < 0.001]. Mean length of the initial hospital stay was 29.6 hours versus 31.8 hours (mean difference = 2.1 hours; 95% CI -3.7 to 8.0 hours, p = 0.462), while median length of initial hospital stay was 8.8 hours versus 14.2 hours (p < 0.001). More patients in the point-of-care group had no inpatient days recorded during follow-up (54% vs 40%, p < 0.001), but mean inpatient days did not differ between the two groups (1.8 vs 1.7, p = 0.815). More patients in the point-of-care group were managed on coronary care [50/1125 (4%) vs 31/1118 (3%), p = 0.041]. There were 36 (3%) patients with major adverse events in the point-of-care group and 26 (2%) in the standard-care group (adjusted OR 1.31; 95% CI 0.78 to 2.20, p = 0.313). Mean costs per patient were £1217 with point-of-care versus £1006 with standard care (p = 0.056), while mean QALYs were 0.158 versus 0.161 (p = 0.250). The probability of standard care being dominant (i.e. cheaper and more effective) was 0.888. CONCLUSIONS: Point-of-care testing increases the proportion of patients successfully discharged home and reduces the median (but not mean) length of hospital stay. It is more expensive than standard care and unlikely to be considered cost-effective. TRIAL REGISTRATION: Current Controlled Trials ISRCTN37823923. FUNDING: This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 15, No. 23. See the HTA programme website for further project information.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In the ED, point-of-care testing has been shown to lead to shorter length of stay in some studies, [15–18] but not in all [19–21].”
From Shorter laboratory turnaround time is associated with shorter emergency department length of stay: a retrospective cohort study (2022) · cites this paper as [18]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Middleware software acts as an intelligent buffer between analyzers and the LIS, performing automatic validation of results based on predefined rules (delta checks, technical flags), releasing up to 80% of normal results instantly without technologist review, and flagging only those needing attention [26].”
From Impact of Laboratory Turnaround Time on Clinical Decision-Making and Patient Outcomes (2024) · cites this paper as [26]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Analysis of Incomplete Multivariate Data
Booth, D. E. (2000) · Technometrics · doi:10.1080/00401706.2000.10486013 · Cited by 5,627
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Thygesen, K. A. (2007) · Circulation · Cited by 3,126
Early Diagnosis of Myocardial Infarction with Sensitive Cardiac Troponin Assays
Reichlin, T., Hochholzer, W., Bassetti, S., Steuer, S., Stelzig, C., Hartwiger, S., Biedert, S., Schaub, N., Buerge, C., Potocki, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900428 · Cited by 1,687
Eagle, K. A., Lim, M. J., Dabbous, O. H., Pieper, K. S., Goldberg, R. J., Van de Werf, F., Goodman, S. G., Granger, C. B., Steg, P. G., Gore, J. M., et al. (2004) · JAMA · doi:10.1001/jama.291.22.2727 · Cited by 1,588
Sensitive Troponin I Assay in Early Diagnosis of Acute Myocardial Infarction
Keller, T., Zeller, T., Peetz, D., Tzikas, S., Roth, A., Czyz, E., Bickel, C., Baldus, S., Warnholtz, A., Fröhlich, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903515 · Cited by 1,150
Representing uncertainty: the role of cost‐effectiveness acceptability curves
Fenwick, E., Claxton, K., & Sculpher, M. (2001) · Health Economics · doi:10.1002/hec.635 · Cited by 1,110
The National Institute for Clinical Excellence (NICE)
Rodgers, A.-T. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.suppl_2.ii92 · Cited by 966
Research works printed but not linked: 48
- [1]1. Goodacre SW, Bradburn M, Cross E, Collinson PO, Gray A, Hall AS on behalf of the RATPAC research team. he RATPAC trial (Randomised Assessment of Treatment using Panel Assay of Cardiac markers): a randomised controlled trial of point-of-care cardiac markers in the emergency department. Heart 2011;97:190-6.
- [3]3. Fitzgerald P, Goodacre SW, Cross E, Dixon S. Cost-efectiveness of point-of-care biomarker assessment for suspected myocardial infarction: the RATPAC trial (Randomised Assessment of Treatment using Panel Assay of Cardiac markers). Acad Emerg Med 2011;18:488-95.
- [5]5. Goodacre S, Cross E, Arnold J, Angelini K, Capewell S, Nicholl J. he health care burden of acute chest pain. Heart 2005;91:229-30.
- [9]9. Bertrand ME, Simoons ML, Fox KAA, Wallentin LC, Hamm CW, McFadden E, et al. Task Force on the Management of Acute Coronary Syndromes of the European Society for Cardiology. Management of acute coronary syndromes in patients presenting without ST elevation. Eur Heart J 2002;23:1809-40.
- [13]13. Collinson PO, Premachandram S, Hashemi K. Prospective audit of incidence of prognostically important myocardial damage in patients discharged from the emergency department. BMJ 2000;320:1702-5.
- [15]15. Goodacre S, Nicholl J, Beahan J, Quinney D, Capewell S. National survey of emergency department management of patients with acute, undiferentiated chest pain. Br J Cardiol 2003;10:50-4.
- [16]16. Collinson PO, John C, Lynch S, Rao A, Canepa-Anson R, Carson E, et al. A prospective randomised controlled trial of point-of-care testing on the coronary care unit. Ann Clin Biochem 2004;41:397-404.
- [19]19. Kendall J, Reeves B, Clancy M. Point of care testing: randomised controlled trial of clinical outcomes. BMJ 1998;316:1052-7.
- [21]21. Balk EM, Ioannidis JPA, Salem D, Chew PW, Lau J. Accuracy of cardiac biomarkers to diagnose acute cardiac ischaemia in the emergency department: a meta-analysis. Ann Emerg Med 2001;37:478-94.
- [22]22. Fesmire FM, Percy RF, Bardoner JB, Wharton DR, Calhoun FB. Serial creatinine kinase (CK) MB testing during the emergency department evaluation of chest pain: utility of a 2-hour deltaCK-MB of +1.6 ng/ml. Am Heart J 1998;136:237-44.
- [23]23. Fesmire FM, Christensen RH, Focy EP, Feintuch TA. Delta creatinine kinase MB outperforms myoglobin at two hours during the emergency department identiication and exclusion of troponin positive non-ST elevation acute coronary syndromes. Ann Emerg Med 2004;44:12-19.
- [25]25. Apple FS, Christensen RH, Valdes R, Andriak Aj, Berg A, Duh SH, et al. Simultaneous rapid measurement of whole blood myoglobin, creatinine kinase MB and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction. Clin Chem 1999;45:199-205.
- [26]26. Newby LK, Storrow AB, Gibler WB, Garvey JL, Tucker JF, Kaplan AL, et al. Bedside multimarker testing for risk stratiication in chest pain units: the CHECKMATE study. Circulation 2001;103:1832-7.
- [34]34. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome. JAMA 2004;291:2727-33.
- [40]40. Goodacre S, Cross E, Lewis C, Nicholl J, Capewell S, on behalf of the ESCAPE Research Team. he ESCAPE cluster randomised trial: efectiveness and safety of chest pain assessment to prevent emergency admissions. BMJ 2007;335:659-62.
- [41]41. Goodacre S, Mason S, Arnold J, Angelini K. Psychological morbidity and health-related quality of life of patients assessed on a chest pain observation unit. Ann Emerg Med 2001;38:369-76.
- [42]42. Conway Morris A, Caesar D, Gray S, Gray A. he TIMI risk score accurately risk stratiies patients with undiferentiated chest pain presenting to an emergency department. Heart 2006;92:1333-4.
- [43]43. Keating L, Benger J, Beetham R, Bateman S, Veysey S, Kendall J, Pullinger R. he PRIMA study: presentation IMA in the emergency department. Emerg Med J 2006;23:764-8.
- [44]44. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost-efectiveness analysis alongside clinical trials: he ISPOR RCT-CEA Task Force Report. Value Health 2001;8:521-33.
- [60]60. Goodacre S, Cross E, Arnold J, Angelini K, Capewell S, Nicholl J. he health care burden of acute chest pain. Heart 2005;91:229-30.
- [61]61. Task Force on the Management of Acute Coronary Syndromes of the European Society for Cardiology. Management of acute coronary syndromes in patients presenting without ST elevation. Eur Heart J 2002;23:1809-40.
- [63]63. Goodacre S, Calvert N. Cost efectiveness of diagnostic strategies for patients with acute, undiferentiated chest pain. Emerg Med J 2003;20:429-33.
- [64]64. Collinson PO, Premachandram S, Hashemi K. Prospective audit of incidence of prognostically important myocardial damage in patients discharged from the emergency department. BMJ 2000;320:1702-5.
- [65]65. Goodacre S, Nicholl J, Dixon S, Cross E, Angelini K, Revill C, et al. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ 2004;328:254-7.
- [66]66. Goodacre S, Nicholl J, Beahan J, Quinney D, Capewell S. National survey of emergency department management of patients with acute, undiferentiated chest pain. Br J Cardiol 2003;10:50-4.
- [67]67. Price CP. Point of care testing. BMJ 2001;322:1285-8.
- [68]68. Fesmire FM, Percy RF, Bardoner JB, Wharton DR, Calhoun FB. Serial creatinine kinase (CK) MB testing during the emergency department evaluation of chest pain: utility of a 2-hour deltaCK-MB of +1.6 ng/ml. Am Heart J 1998;136:237-44.
- [69]69. Fesmire FM, Christensen RH, Focy EP, Feintuch TA. Delta creatinine kinase MB outperforms myoglobin at two hours during the emergency department identiication and exclusion of troponin positive non-ST elevation acute coronary syndromes. Ann Emerg Med 2004;44:12-19.
- [70]70. Ebell MH, Flewelling D, Flynn CA. A systematic review of troponin T and I for diagnosing acute myocardial infarction. J Fam Pract 2000;49:550-6.
- [71]71. Balk EM, Ioannidis JPA, Salem D, Chew PW, Lau J. Accuracy of cardiac biomarkers to diagnose acute cardiac ischaemia in the emergency department: a meta-analysis. Ann Emerg Med 2001;37:478-94.
- [74]74. Apple FS, Christensen RH, Valdes R, Andriak Aj, Berg A, Duh SH, et al. Simultaneous rapid measurement of whole blood myoglobin, creatinine kinase MB and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction. Clin Chem 1999;45:199-205.
- [75]75. Newby LK, Storrow AB, Gibler WB, Garvey JL, Tucker JF, Kaplan AL, et al. Bedside multimarker testing for risk stratiication in chest pain units: the CHECKMATE Study. Circulation 2001;103:1832-7.
- [76]76. Caragher TE, Fernandez BB, Jacobs F, Barr LA. Evaluation of quantitative cardiac biomarker point of care testing in the emergency department. J Emerg Med 2002;22:1-7.
- [77]77. Ng SM, Krishnaswamy P, Morissey R, Clopton P, Fitzgerald R, Maisel AS, et al. Ninety- minute accelerated critical pathway for chest pain evaluation. Am J Cardiol 2001;88:611-17.
- [79]79. Collinson PO, John C, Lynch S, Rao A, Canepa-Anson R, Carson E, et al. A prospective randomised controlled trial of point-of-care testing on the coronary care unit. Ann Clin Biochem 2004;41:397-404.
- [80]80. Kendall J, Reeves B, Clancy M. Point of care testing: randomised controlled trial of clinical outcomes. BMJ 1998;316:1052-7.
- [83]83. Panteghini M, Pagani F, Yeo KT, Apple FS, Christenson RH, Dati F, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 2004;50:327-32.
- [84]84. Antman EM, Cohen M, Berninck PJ, Horacek T, Papuchis G, Mautner B, et al. he TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835-42.
- [85]85. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome. JAMA 2004;291:2727-33.
- [86]86. Goodacre S, Mason S, Arnold J, Angelini K. Psychological morbidity and health-related quality of life of patients assessed on a chest pain observation unit. Ann Emerg Med 2001;38:369-76.
- [87]87. Conway Morris A, Caesar D, Gray S, Gray A. he TIMI risk score accurately risk stratiies patients with undiferentiated chest pain presenting to an emergency department. Heart 2006;92:1333-4.
- [88]88. Keating L, Benger J, Beetham R, Bateman S, Veysey S, Kendall J, Pullinger R. he PRIMA study: presentation IMA in the emergency department. Emerg Med J 2006;23:764-8.
- [93]93. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost efectiveness acceptability curves. Health Econ Lett 2001;10:779-87.
- [95]95. Rubin D. Multiple imputation for nonresponse in surveys. New York: J Wiley & Sons; 1987.
- [96]96. Briggs A. Probabilistic analysis of cost-efectiveness models: statistical representation of parameter uncertainty. Value Health 2005;8:1-2.
- [98]98. Collinson PO, Gaze DC, Bainbridge K, Morris F, Morris B, Price A, et al. Utility of admission cardiac troponin and ischemia modiied albumin (IMA) measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department. Emerg Med J 2006;23:256-61.
- [99]99. Gray A, Goodacre S, Newby D, Masson M, Sampson F, Nicholl J, on behalf of the 3CPO trialists. Efectiveness of non-invasive ventilation in patients with acute severe cardiogenic pulmonary oedema. New Engl J Med 2008;359:142-51.
- [101]101. Tsang DM, Owen AM, Collinson PO, Barth JH. Surveys on the use of cardiac markers in the United Kingdom. Ann Clin Biochem 2003;40:138-42.
Cited by
Walters, S. J., Bonacho dos Anjos Henriques-Cadby, I., Bortolami, O., Flight, L., Hind, D., Jacques, R. M., Knox, C., Nadin, B., Rothwell, J., Surtees, M., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015276 · Cited by 560
Cook, J., Hislop, J., Adewuyi, T., Harrild, K., Altman, D., Ramsay, C., Fraser, C., Buckley, B., Fayers, P., Harvey, I., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18280 · Cited by 194
Emergency Department Crowding: Time for Interventions and Policy Evaluations
Boyle, A., Beniuk, K., Higginson, I., & Atkinson, P. (2012) · Emergency Medicine International · doi:10.1155/2012/838610 · Cited by 168
Westwood, M., van Asselt, T., Ramaekers, B., Whiting, P., Thokala, P., Joore, M., Armstrong, N., Ross, J., Severens, J., & Kleijnen, J. (2015) · Health Technology Assessment · doi:10.3310/hta19440 · Cited by 161
The state of point-of-care testing: a european perspective
Larsson, A., Greig-Pylypczuk, R., & Huisman, A. (2015) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2015.1006347 · Cited by 159
“Decreased TATs also can result in the earlier identification of negative cases of ACS, thereby increasing the number of successful discharges, and allowing for more efficient use of hospital resources (11).”
Background
Metadata
- Authors
- Goodacre, S., Bradburn, M., Fitzgerald, P., Cross, E., Collinson, P., Gray, A., & Hall, A.
- Affiliations
- University of Sheffield (GB)
- St George's Hospital (GB)
- Edinburgh Royal Infirmary (GB)
- Corresponding author
- Goodacre, S
- Venue
- Health Technology Assessment
- Published
- 2011-05
- Volume
- 15
- Issue
- 23
- Pages
- iii-xi, 1
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W1932997227
- Cited by
- 64
- References
- 44
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 7 · 2016: 6 · 2015: 6 · 2014: 5 · 2013: 5 · 2012: 7
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Health Technology Assessment (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- UWE Research Repository (UWE Bristol) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Health Technology Assessment programme (06/302/19)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Emergency Medicine › Emergency and Acute Care Studies
- Health Sciences › Medicine › Family Practice › Clinical Reasoning and Diagnostic Skills
- Keywords
- acute myocardial infarction, emergency department, chest pain, diagnostic testing, discharge decisions, major adverse events, cost-effectiveness, quality-adjusted life years, length of hospital stay, clinical effectiveness, coronary artery disease, cardiac arrhythmias, economic evaluation
- MeSH terms
- Adult, Aged, Cost-Benefit Analysis, Emergency Service, Hospital, Female, Health Status, Humans, Length of Stay, Male, Middle Aged, Myocardial Infarction, Myoglobin, Risk Factors, Sensitivity and Specificity, Troponin, Biomarkers, Patient Satisfaction, Quality-Adjusted Life Years, Point-of-Care Systems, Creatine Kinase, MB Form
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.